The introduction of inter partes review (IPR) altered the U.S. patent landscape significantly upon its introduction by the America Invents Act in 2012. Through July 2016, the PTO has received nearly 5000 petitions. While the majority of petitions are directed to patents in the electrical/computer arts, the number of petitions filed against pharmaceutical and biotech patents has almost doubled since 2014.
In this program, presenters Angus Chen and Andrew Wasson, partners at Haug Partners LLP, will survey the use of IPR petitions in the pharmaceutical and biotechnology industries. They will review the basic framework of an IPR proceeding, summarize key pharma and biotech petition decisions, and discuss how recent changes to the rules may affect strategy. They will also consider how IPRs in pharma and biotech factor into other litigation and regulatory strategy decisions. Additionally, the program will include a discussion of other important developments, such as the use of IPR proceedings by non-practicing entities.
As a partner at Haug Partners LLP, Angus Chen draws on his legal and scientific background to strategically navigate the dynamic area at the intersection of law and science.
Motivated by the desire to have a real life impact on people and their health, Dr. Chen’s practice also benefits from his prior experience as in-house Patent Counsel for a specialty pharmaceutical company, which has provided him with the ability to effectively integrate clients’ interests and a business perspective into his practice.
Dr. Chen’s work at FLH focuses on intellectual property litigation, counseling, opinion and agreement work. He specializes in the pharmaceutical patent and regulatory laws under the Hatch-Waxman Amendments to the Federal Food, Drug & Cosmetic Act. Dr. Chen has extensive experience with both brand and generic pharmaceuticals, including with respect to patent and regulatory strategies, lifecycle management, and settlement agreements.
Andrew Wasson is a partner in the New York office of Haug Partners LLP. Andrew has a broad range of experience in both the brand and generic side of pharmaceuticals, especially with respect to issues involving intellectual property law and regulatory law.
Having grown up with a father who is a patent lawyer, Mr. Wasson has been involved in patents in one way or another for the better part of his life and has the advantage of being able to deal with complex patent law concepts in a very natural way. Mr. Wasson is registered to practice before the U.S. Patent and Trademark Office and has published extensively in both scientific and legal literature.
Mr. Wasson also serves on the Editorial Advisory Board for FDLI's Update Magazine.
The speakers were very informative and knowledgeable. I think it was a presented at quite an advanced level.
good team, good delivery
Yet another subject I was clueless about before watching. Good presenters.
Great presentation. Thank you.
very helpful presentation
Unlimited CLE Subscription gives you access to take almost any course from our catalog and earn as much CLE credit as you need.